150 Outcomes After Curative-Intent Radiotherapy for Lung Cancer with Driver Mutations: A Retrospective Multicentre Case-Control Study
Molecular analysis is increasingly available for non-metastatic NSCLC across the UK. Whilst patients with NSCLC and driver mutations have worse outcomes following surgery, chemotherapy and immunotherapy compared to patients with ‘wildtype’ tumours, there is a dearth of outcome data in the setting of curative-intent radiotherapy. A retrospective, multicentre, case-control study was undertaken by the British Thoracic Oncology Group trainee network in order to determine if common driver mutations impact outcomes after radi otherapy. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Salman Ashraf, Madeha Khan, Nada Naguib, Robert Rulach, Katharine Welsh, Rebecca Carozzi, Ashley Horne, Amelia Payne, Mary Denholm, Georgia Stewart, Ahmed Bedair, Stephen Harrow, Corinne Faivre-Finn, Jonathan McAleese, Gerard Hanna, Allan Hackshaw, Fiona Tags: Radiotherapy Source Type: research
151 Patient outcomes following Lung SABR: The University Hospitals Dorset Experience
University Hospitals Dorset (UHD) began delivering stereotactic ablative body radiotherapy (SABR) for primary and oligometastatic lung cancer in May 2021. Referral criteria were as per the National SABR consortium guidelines. This retrospective study was performed to assess patient outcomes following lung SABR including toxicities, rates of progression/ recurrence and survival. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Emma Mackenzie, Jonathan Ah-Chuen, Mike Bayne, Mark Noble, Deborah Scott Tags: Radiotherapy Source Type: research
152 A retrospective audit comparing toxicity and survival outcomes in patients who received palliative radiotherapy for NSCLC using the COVID-19 hypofractionated regime with patients treated pre-pandemic using standard RCR recommended regimes
The World Health Organisation (WHO) declared COVID-19 a pandemic on 11th March 2020. To mitigate risk of vulnerable lung cancer patients being exposed to COVID-19 due to multiple hospital visits, a contingency hypo-fractionated palliative lung radiotherapy protocol was adopted. This audit aimed to retrospectively evaluate the toxicity and 1 year overall and progression-free survival for different palliative radiotherapy schemes in NSCLC patients. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Lynn Bell, Louise Turtle, Tony Pope, David Cobben, Anoop Haridass Tags: Radiotherapy Source Type: research
153 Lattice radiotherapy (LRT): Safely Dose Escalating Palliative Radiotherapy
Lattice radiotherapy (LRT) is a novel technique of delivering inhomogeneous doses of radiation to voluminous tumours. LRT is relevant in the treatment of large tumour volumes where standard palliative radiotherapy doses are unlikely to achieve meaningful tumour and symptom control, and dose escalation to the entire PTV is likely to carry a significant risk of increased toxicity. For lattice radiotherapy, a 3D-array of focal hot spots called vertices are created within the tumour PTV. The vertices are postulated to produce more efficient immunogenic cell death whilst the remainder of the PTV is covered by a standard palliat...
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Anna Lerner, Aryeh Greenberg, Sweta Bowles, Niall MacDougall, John Conibear Tags: Radiotherapy Source Type: research
154 The 2023 Royal College of Radiologists (RCR) National re-audit of radical radiotherapy for Non small cell lung cancer (NSCLC) – changing Standards of Care in UK practice
The Royal College of Radiologists ’ (RCR) audit of radical radiotherapy (RR) for patients with non-small cell lung cancer (NSCLC) in 2013 found evidence of under-treatment compared to international comparators, marked variability between cancer networks (CN), elderly patients less likely to receive guideline recommended treatments (GRT), and a low access to technology. Various national and local interventions have since been completed. Our 2023 re-audit has demonstrated a 70% increase in RR with less variability in GRT for the elderly, but similar variation between CN. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Jonathan McAleese, Karl Drinkwater Tags: Radiotherapy Source Type: research
155 Advanced Practice Clinical technologist contouring GTV volumes for radical lung radiotherapy
Radical radiotherapy (RR) is a curative treatment for lung cancer. In the UK, contouring of gross tumour volume (GTV) is mostly (99.4% of the time) performed by consultant clinical oncologists (CO) with the remaining 0.6% by clinical site specialist radiographers (CSSR). RR has increased over the past decade. In the Northern Ireland Cancer Centre (NICC) there has been an exponential rise, with 124 patients in 2013 and 236 in 2022. This increased workload has put strain on the radiotherapy workforce, including those hitherto involved in GTV contouring (CO, their trainees and CSSR). (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Sarah Louise Black, Catherine Nelson, Jonathan McAleese, Gerry G Hanna, Cathryn Crockett, Karen Tumelty, Gerard Walls, Jolyne O'Hare, Linda Young, Pat O'Shea Tags: Radiotherapy Source Type: research
156 Increasing re-planning rates for radical lung radiotherapy – the role of frequent cone beam IGRT and tumour size
Successful radical radiotherapy (RR) for lung cancer is dependent on accurately targeting areas of active disease with high doses of radiation result in geographic miss and under-treatment of areas of active disease. Regular imaging checks during treatment (IGRT) by skilled radiographers, help to ensure accuracy by altering setup to match with the radiotherapy plan. However significant intratarget changes, such as progression of local disease (lPD), or peri-target changes, such as collapse or re-expansion of the lung, may require a complete re-plan (re-P), which requires a duplication of all planning steps. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Bernard Kearney, Gerry G Hanna, Cathryn Crockett, Jolyne O'Hare, Karen Tumelty, Gerard Walls, Jonathan McAleese, Linda Young Tags: Radiotherapy Source Type: research
157 Establishing a multidisciplinary habilitation clinic for lung cancer patients receiving radical radiotherapy
Advancing techniques and efficacy of new drug therapies have changed the status of radiotherapy within the management of stage III lung cancer in recent years, increasing the demand for radical intent concurrent chemo-radiotherapy (CCRT). A good level of physical& psychological fitness is required to cope with the rigours of CCRT, this needs to be maintained to access subsequent immunotherapy or surgery and for realisation of potential survival outcomes. Pre-surgical ‘prehabilitation’ has proven to benefit both patient experience and service efficiencies and have been funded for some years. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Emma Wingate, Qamar Ghafoor, Charlotte Wardzyndski, Leah Grindrod, George Reeves, Lucy Damms Tags: Radiotherapy Source Type: research
158 Who gets acute oesophagitis with radical radiotherapy for locally-advanced non-small cell lung cancer (NSCLC)?
Oesophagitis is common in people treated with radical radiotherapy for locally-advanced NSCLC. Acute oesophagitis and poor nutrition may lead to treatment breaks, early cessation of planned treatment and poorer outcomes. This retrospective audit aimed to explore the possible association between oesophagitis and oesophageal radiation dose alongside nutritional support needs in people with stage 3 NSCLC. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Sangary Kathirgamakarthigeyan, Catherine Sharma, Laura Miller, Ashleigh Butcher, Karen Foweraker, Kerstie Johnson, Mayuran Ananth Sivanandan, Joon Wee Ho, Abigail Pascoe Tags: Radiotherapy Source Type: research
159 Outcomes of thoracic radiotherapy for oligoprogression after a response to Pembrolizumab in patients with advanced Non-Small Cell Lung Cancer
Immunotherapy is the standard of care first line treatment for incurable non-oncogene addicted Non-Small Cell Lung Cancer (NSCLC). There is limited data on thoracic high dose radiotherapy after immunotherapy. Our aim was to assess efficacy and toxicity of radiotherapy, for thoracic oligoprogression after documented response to pembrolizumab in patients with advanced NSCLC. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Dhania Haron, Iain Phillips, Stephen Harrow, Tamasin Evans, Kirsty MacLennan, Sorcha Campbell, Melanie Mackean, Colin Barrie, Mark Stares Tags: Radiotherapy Source Type: research
160 Updating primary care smoking records by text message in preparation for lung cancer screening in Wales
Targeted lung cancer screening requires identification of current and ex-smokers ( “ever-smokers”). Primary care records can be used to identify ever-smokers but the completeness and accuracy of this data is variable, and updating records can be resource-intense. We assessed the completeness of smoking data (recorded as “tobacco codes”) in primary care records in Wales and developed a toolkit to update missing smoking status data using an automated text message system. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Sinan Eccles, Jean Engela-Volker, Nicole Abel, Amy Smith, Claire Wright, Chris Coslett Tags: Screening Source Type: research
161 Healthcare professionals ’ communication practices for disclosing LDCT-detected pulmonary nodules to patients undergoing surveillance
Low-dose computed tomography (LDCT) screening can detect indeterminate pulmonary nodules, which carry a low risk of lung cancer (LC) but require surveillance scans. Healthcare professionals ’ (HCPs) communication can reduce patients’ distress, uncertainty and concern, but nodule communication practices in the UK have yet to be examined. This multicentre qualitative study aimed to explore HCPs’ experiences and communication practices for disclosing LDCT-detected pulmonary nodule d iagnoses to patients undergoing surveillance. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Evangelos Katsampouris, Andrew Creamer, Ruth Prendecki, Daisy McInnerney, Elizabeth Clark, Jennifer L. Dickson, Richard Lee, Samuel M. Janes, Stephen W. Duffy, Samantha L. Quaife Tags: Screening Source Type: research
162 The LungScot study: overview of findings from a feasibility and acceptability of lung screening in Scotland
The LungScot study aims to pilot lung screening in Scotland using low dose computed tomography, in order to explore its feasibility, acceptability, and implementation challenges. We aimed to understand people's views on, and barriers and facilitators to, lung screening, to test the process for lung screening in Scotland. This presentation will give an update on the findings to from the pilot study in four Scottish health boards, and qualitative feedback. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Debbie Cavers, Edwin van Beek, Ahsan R Akram, Graeme Dickie, Christine Campbell, Katie A Robb, Frank Sullivan, Melanie Mackean, Aileen Neilson, Robert C Steele, Lynsey Brown, David Weller Tags: Screening Source Type: research
163 Optimising uptake of the Lung Health Check Operational Pilot within a socioeconomically deprived area of Wales
The Lung Health Check (LHC) Operational Pilot for Wales will enable preparation for a national lung cancer screening programme roll-out. Known barriers to participation in LHCs include smoking-related stigma, fear and fatalism, particularly amongst those living in socioeconomically deprived areas. We used evidence-based best practice when planning the Operational Pilot with the aim of optimising uptake. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Chris Coslett, CIaire Wright, Amy Smith, McCutchan Grace, Samantha Quaife, Kate Brain, Dafydd Snelling, Heather Ramessur-Marsden, Sinan Eccles Tags: Screening Source Type: research
164 Participant recollection of recent imaging is unreliable for determining eligibility for lung cancer screening
Targeted low-dose CT screening for lung cancer has been recommended for implementation in the UK and is already underway in England as Targeted Lung Health Checks (TLHCs). Individuals who have undergone thoracic CT imaging in the last 12 months, or are planned to in the next 3 months, are unlikely to benefit and should be deferred. The TLHC standard protocol states that “if a participant mentions [a prior thoracic CT], reasonable steps should be taken to assess whether [this] has taken place.” We explored frequency and participant recollection of previous imaging in the Lung Health Check (LHC) Operational Pilot (OP) fo...
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Elizabeth Sharkey, Lyndsey Haffenden, Julie Thomas, Sinan Eccles Tags: Screening Source Type: research
